ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Aqueous Humor Metabolomics in Different Stages of Diabetic Retinopathy Based on Ultra - Performance Liquid Chromatography - Tandem Mass Spectrometry.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To search for differential metabolites in patients with proliferative diabetic retinopathy (PDR), patients with nonproliferative diabetic retinopathy (NPDR), and control subjects, and to study their potential biomarkers in depth. Patients and Methods: An untargeted metabolomic approach based on ultra-performance liquid chromatography-tandem mass spectrometry was used to study aqueous humor from 63 patients with PDR, 37 patients with NPDR, and 30 non-diabetic controls. Differential metabolites in different periods of diabetic retinopathy (DR) were identified using orthogonal projections to latent structure discriminant analysis and fold-change. Further logistic regression and receiver operating characteristic curve analysis were performed to select and validate potential biomarkers. Results: Compared to the control group, the PDR group had 80 differential metabolites, among which 3-methylhistamine, N-acetyl-L-histidine, and cytosine were identified as potential biomarkers, whereas the NPDR group had 94 differential metabolites, among which and N-acetyl-L-histidine and hypoxanthine were identified as potential biomarkers. Relative to the PDR and NPDR groups, 5-hydroxyindole-3-acetic acid and L-3-hydroxykynurenine may be potential biomarkers suggesting DR developmental stage or progression. Conclusion: The metabolite profiles identified in this study provide insights into the mechanisms of DR onset and progression in future studies and may eventually inform the development of metabolic biomarkers for prognosis and new therapeutic strategies for DR management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.